Enzo Life Sciences has expanded its portfolio of drug discovery screening platforms with the introduction of the new Leading Light™ Wnt Reporter Assay.
Alterations in Wnt expression, surface receptors, signaling partners, and the battery of Wnt-regulated genes (collectively the canonical Wnt pathway) are known to manifest in a variety of clinically relevant disease states, including cancer, osteoporosis, cardiovascular disease, diabetes, and neurodegeneration. Development of Wnt pathway altering drugs requires the ability to rapidly screen the effect of compounds and biological therapeutics on the expression of Wnt-regulated genes. The Leading Light™ Wnt Reporter Assay was developed to meet the market need for a high sensitivity system that accelerates screening analysis of Wnt pathway modulators. This product is a luciferase-based assay for the analysis of canonical Wnt signaling. The Leading Light™ Wnt Reporter Assay guarantees confidence in the assay results by providing a system that is capable of detecting low concentration of effectors with across a dynamic range of signal intensity.
The assay uses a 3T3 mouse fibroblast cell line modified with a luciferase reporter gene under the control of Wnt-responsive promoters (TCF/LEF). It provides a true endpoint detection system for screening compounds without the need for overexpression or alteration of pathway signaling molecules. With a chemiluminescent readout amenable to both 96-well and 384-well plate formats, the kit allows for high-throughput analysis of Wnt pathway activators and inhibitors. The Leading Light™ Wnt Reporter Assay Starter Kit is supplied with an easy-to-follow protocol, a validated cell line and all necessary media, reagents and controls.
With this complete kit, Enzo Life Sciences enables scientists to achieve faster, more reproducible results. The Leading Light™ Wnt Reporter Assay Starter Kit is the most recent addition to the Enzo product line for Wnt research. The Leading Light™ Wnt Reporter Assay along with the Screen-Well® Wnt Pathway Library and numerous ELISAs, antibodies and proteins combine to provide a total solution to Wnt-related research needs.
For more information on, or to order the Leading Light Wnt Reporter Assay or other Enzo Life Sciences products, please visit us at www.enzolifesciences.com or call us at 1-800-942-0430.
Enzo Life Sciences, Inc. is a wholly owned subsidiary of Enzo Biochem, Inc. headquartered in Farmingdale, New York. The company is focused on providing innovative life science research reagents worldwide based on nearly 40 years of successful experience in building strong international market recognition, implementing outstanding operational capabilities, and establishing a state-of-the-art electronic information and ordering marketplace.
Enzo Life Sciences, Inc. is a recognized leader in labeling and detection technologies across research and diagnostic markets. Our strong portfolio of assay kits, fluorescent dyes, small molecules, antibodies, proteins, peptides, and compound libraries provides life science researchers tools for target identification/validation, drug discovery, high content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
New Product Release
Date: November 6, 2012
For additional Information, please contact:
Kara Cannon, Global Head of Marketing
1-631-694-7070 x 145
